PFE Stock Price Today (July 2026) — Pfizer Inc. Analysis & Key Metrics 2026-07-17
Pfizer Inc. (PFE) is trading at $25.05, down 0.36% today (as of July 2026). The stock continues to show early recovery signs above the short-term average, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $29.15 (16.4% upside).
- Volatility remains elevated (17.83% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (5.40% YoY) alongside significant competitive pressures.
PFE Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Pfizer Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $189.20B
P/E Ratio
Forward P/E: 8.51
Revenue Growth
Year over Year
Analyst Target
+16.4% upside potential
Key Investor Questions About PFE
What investors need to know before buying
Based on current market data, PFE presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 58.39)
- Fundamentals say: Caution warranted (high leverage concerns)
PFE's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for PFE investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $64.73B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, PFE stock traded between $23.11 and $28.75—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 17.83% annualized volatility and β=0.45, the stock exhibits low sensitivity to market moves—making PFE suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Pfizer Paid Out $14.6 Billion in Dividends Over the Last 18 Months. Can It Keep This Up Through the Patent Cliff?
Pfizer's dividend yield is 7% for a very good reason: investors are worried about the risk of a dividend cut.
The Real Question Buried Inside Merck Stock's Premium Price
The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.
Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move.
Gilead stock is closely tied to its HIV treatments. But with Biktarvy's patent expirations looming, can the giant survive?
Boomers Swear by These High-Yield 5% and More Kings They Can Buy and Hold Forever
When a regular paycheck disappears in retirement, the stakes of every investment decision skyrocket. These five high-yield stocks earning 6% or more are winning over Boomers who refuse to let rising prices eat their savings alive.
Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances
The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech inked another deal and Insmed strengthened support for a closely watched blood pressure drug.
3 High-Yield Dividend Stocks to Buy and Hold
All three can be bought on the dip.
ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?
On July 8, Arbutus received around $178 million from Moderna as part of a patent litigation settlement, the company said.
Pfizer (PFE) Stock Looks Fairly Priced With Pipeline Risks In View
After a tough stretch for shareholders over the last five years, with Pfizer stock down about 22% over that window, the current valuation sits in a middle ground where the broader pricing checks look mixed rather than clearly cheap or clearly expensive. Pfizer has delivered a decline of roughly 22% over five years, which frames any current pricing as a potential reset rather than the tail end of a long rally. Recent approvals and oncology progress can support expectations for future cash...
Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?
PFE trades below key moving averages as investors weigh fading COVID sales against pipeline growth, acquisitions and a low valuation with a high dividend.
What Could Push LLY Stock Higher From Here?
While the market focuses on a single class of blockbuster drugs, a different story is unfolding inside the company. Lilly’s immunology, oncology, and neuroscience medicines are quietly compounding at a blistering pace. These other therapeutic areas collectively grew by 160% last quarter, a rate that suggests a much broader growth engine is taking shape.
Frequently Asked Questions
Common investor questions about Pfizer Inc.
Pfizer Inc. (PFE) is currently trading at $25.05. The RSI (14-day) is at 58.4, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $29.15 implies 16.4% upside from current levels. Volatility is low at 17.8% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Pfizer Inc. (PFE): The trailing P/E ratio is 19.12, which is in line with broader market averages. The forward P/E is 8.51, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 2.81, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 1.58. Price-to-Sales is 2.25. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 27 analysts covering PFE, the consensus price target is $29.15. This represents a 16.4% upside from the current price of $25.05. The range spans from a low target of $24.00 to a high target of $36.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Pfizer Inc. (PFE) pays a dividend with a current yield of approximately 6.87%. The annualized dividend rate is $1.72 per share. The payout ratio is 131.3%, which exceeds 100%—this means the company is paying out more than it earns, which may not be sustainable long-term. The most recent ex-dividend date was 2026-07-24T00:00:00.000Z.
Key risks for Pfizer Inc. (PFE) investors include: 1. Unsustainable dividend payout ratio (131%) could lead to a dividend cut. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Pfizer Inc.'s (PFE) current debt and financial health profile: Total debt stands at $64.73B. The debt-to-equity ratio is 71.60, which is moderate and generally manageable for most companies. The current ratio is 1.25, indicating adequate short-term liquidity. The quick ratio is 0.85. The company holds $13.08B in cash and equivalents. Free cash flow is positive at $12.38B, providing a cushion for debt servicing and shareholder returns.